title: [Remodeling of the cardiovascular system and development of chronic kidney disease in patients with metabolic syndrome and obesity: role of eNOS, subunit p22-phox of NADPH-oxidase and MTHFR genes].
abstract: OBJECTIVE
  To examine contribution of polymorphisms of genes of endothelial NO-synthase (eNOS), NADPH-oxidase and methylenetetrahydrofolate reductase (mTHFR) to development of remodeling of cardiovascular system and chronic disease of the kidneys (CDK) in patients with metabolic syndrome (mS) and obesity. MATERIAL AND METHODS. Standard clinical and device examinations were made and polymorphisms C242T of gene of subunit p22-phox of NADPH-oxidase, G894T of gene of eNOS and C677T of gene of MTHFR were studied in 66 MS patients (49 males and 17 females, age 19-62 years.
  
  
  RESULTS
  The presence of even one prognostically poor allele variants of the genes studied was registered in 83 examinees. The genotype 242TTp22-phox of NADPH-oxidase subunit was associated with the highest insulin resistance, allele 894T of gene eNOS- with reduced glomerular filtration rate and progression of left ventricular hypertrophy.
  
  
  CONCLUSIONS
  Polymorphism of the genes the products of which modulate endothelial function can be considered as potential predictors of severity of MS target organs impairment.
authors.forename: E A
authors.initials: EA
authors.lastname: Saginova
authors.forename: M G
authors.initials: MG
authors.lastname: Galliamov
authors.forename: A V
authors.initials: AV
authors.lastname: Balatskiĭ
authors.forename: A V
authors.initials: AV
authors.lastname: Kolotvin
authors.forename: M V
authors.initials: MV
authors.lastname: Severova
authors.forename: L M
authors.initials: LM
authors.lastname: Samokhodskaia
authors.forename: V V
authors.initials: VV
authors.lastname: Fomin
authors.forename: T N
authors.initials: TN
authors.lastname: Krasnova
authors.forename: N A
authors.initials: NA
authors.lastname: Mukhin
mesh_terms: D000328:Adult; D004730:Endothelium, Vascular / Q000201:enzymology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000201:enzymology / Q000209:etiology* / Q000235:genetics; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D019255:NADPH Oxidases / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III / Q000235:genetics*; D009765:Obesity / Q000150:complications* / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D011237:Predictive Value of Tests; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000201:enzymology / Q000209:etiology* / Q000235:genetics; D012720:Severity of Illness Index; D020257:Ventricular Remodeling / Q000235:genetics; D055815:Young Adult
chemical_list: C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D019255:NADPH Oxidases; C086986:CYBA protein, human